Authors
Hossein Ahmadi, Ahmad Reza Jamshidi, Farhad Gharibdoost, Mahdi Mahmoudi, Noushin Rastkari, Shayan Mostafaei, Mohammad Javad Fattahi, Mahdi Vojdanian, Salvatore Cuzzocrea, Bernd HA Rehm, Hidenori Matsuo, Mostafa Hosseini, Zahra Aghazadeh, Seyed Shahabeddin Mortazavi-Jahromi, Abbas Mirshafiey
Publication date
2018/6
Journal
Inflammopharmacology
Volume
26
Pages
737-745
Publisher
Springer International Publishing
Description
Background
Following the potent efficacy of β-d-mannuronic acid (M2000) in phase I/II trial in ankylosing spondylitis patients, the present clinical trial was conducted to evaluate the efficacy, safety, and tolerability of this novel drug in rheumatoid arthritis (RA) patients who had inadequate response to conventional therapy.
Method
The study was a 12-week randomized, controlled, phase I/II clinical trial with two treatment arms: M2000 and conventional treatment. Patients who had RA according to the modified American College of Rheumatology (ACR) criteria, with active disease at baseline also inadequate response to conventional therapy, were enrolled in this study. M2000 was administrated at a dose of two capsules (500 mg) per day orally during a period of 12 weeks. The primary endpoint was the proportion of patients fulfilling the ACR 20 …
Scholar articles
H Ahmadi, AR Jamshidi, F Gharibdoost, M Mahmoudi… - Inflammopharmacology, 2018